Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00337129 · ClinicalTrials.gov registry record · Phase 2
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00337129: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00337129 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00337129, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well E7389 works in treating patients with metastatic or recurrent head and neck cancer.
Interventions
- DRUG eribulin mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00337129
The ClinicalTrials.gov registry entry for NCT00337129 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eribulin mesylate is the first listed.
NCT00337129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00337129 about?
NCT00337129 is a clinical study titled "S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well E7389 works in treating patients with metastatic or recurrent head and nec...
What is the current status of trial NCT00337129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2006-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00337129?
The interventions under investigation include: eribulin mesylate (DRUG).
Who is sponsoring clinical trial NCT00337129?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.